Hormone therapy may confer more aggressive properties to prostate tumors
Hormone therapy has serious side effects and is therefore used only when the tumour has grown too large to be treated in any other way, or when the tumour has spread and formed metastases. The hormone that is given causes the natural production of male sex hormone to fall, and the tumour stops growing. Pain also usually decreases.
"Our results suggest that the tumour properties change following hormone therapy such that the tumours at a later stage can continue to grow and spread in the body. For this reason, it is probably necessary to supplement the hormone therapy in order to compensate for these changes", says pharmacist Karin Jennbacken, author of the thesis.
The results show that patients who have been given hormone therapy have higher levels of the proteins that enable the cancer cells to move through the body and attach to other organs. One of these proteins is known as "N-cadherin", and this protein is present in higher levels in patients who have been given hormone therapy. "We don't have any good treatment alternatives in cases where the tumour returns after hormone therapy, and this means that it is particularly important to study how such tumours are controlled and how they behave. The properties that we have identified may become targets for new anti-metastatic drugs in advanced prostate cancer", says Karin Jennbacken.
Topics
Organizations
Other news from the department science
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.